ACI is currently enrolling patients in a multicenter, randomized, double-masked, placebo-controlled clinical trial to evaluate a novel investigational product in dogs with stage 3 intranasal adenocarcinoma.

Participation Requirements

• Patients will receive radiation therapy and investigational product or placebo intravenously under general anesthesia for 5 consecutive days.
• Patients will be required to visit study site for regularly scheduled appointments over a 4-month period.
• Owners will be required to document study associated observations and questionnaires as appropriate.

Study Benefits

• If you elect to enroll your dog in the study, the investigational drug will be funded at no charge to you.
• The study site will discuss the other veterinary services that are covered at no cost to you if your pet is eligible.

Eligibility Criteria

• Dog is ≥ 12 months of age
• Dog weighs > 5kg
• Dog has ECOG performance status less ≤ 1
• Dog has stage 3 intranasal adenocarcinoma and is amenable to radiotherapy
• Dog is able to tolerate multiple anesthesia events
• No prior radiotherapy, chemotherapy, or surgical therapy prior to enrollment
• No clinically significant cardiovascular arrhythmias

The Veterinary Investigator at the study site will determine if your pet meets other eligibility criteria and may enroll in the study.

Study Sites

Gulf Coast Veterinary Specialists
8042 Katy Freeway
Houston, TX 77024

Iowa State University
1800 Christensen Drive
Ames, Iowa 50011

Kansas State University
1800 Denison Avenue
Manhattan, KS 66506

Purdue University
625 Harrison Street
West Lafayette, IN 47907

Southwest Veterinary Oncology
141 E. Ft. Lowell Rd
Tucson, AZ 85705

The Ohio State University
601 Vernon L. Tharp Street
Columbus, OH 43210

University of Florida
2015 SW 16th Ave
Gainesville, FL 32608

University of Illinois
1008 W Hazelwood Dr.
Champaign-Urbana, IL 61802